# Biotech Daily Digest — 2025-10-09

**43 items from 4 sources**

## Summary by Source

- Endpoints News: 13 items
- Fierce Biotech: 10 items
- Regeneron Press Releases: 1 item
- arXiv q-bio: 19 items


## Endpoints News

- **[What's behind Amazon’s in-person pharmacy play](https://endpoints.news/whats-behind-amazons-in-person-pharmacy-play/)**  
  _Thu, 09 Oct 2025 14:41:26 +0000_  
  Yesterday, Amazon said it will start setting up machines that can dispense prescription medication at its One Medical clinics.

 It’s not a new piece of technology (in fact, it's basically ...

- **[Chinese biotechs work on cheaper alternatives to $2M Zolgensma](https://endpoints.news/chinese-biotechs-work-on-cheaper-alternatives-to-2m-zolgensma/)**  
  _Thu, 09 Oct 2025 14:00:08 +0000_  
  When Nirnay Murthy learned about a treatment for his toddler son’s rare condition, relief quickly gave way to disappointment.

 A one-time gene therapy called Zolgensma from the Swiss drugmaker Novartis can halt spinal muscular atrophy ...

- **[Otsuka Precision Health buys maternal meditation platform Mindful Mamas](https://endpoints.news/otsuka-precision-health-buys-maternal-meditation-platform-mindful-mamas/)**  
  _Thu, 09 Oct 2025 13:32:57 +0000_  
  Otsuka Precision Health, a subsidiary of the drugmaker Otsuka that's focused on digital health, has acquired Mindful Mamas, a maternal mental wellness startup offering meditation, Endpoints News has learned exclusively.

 Co-founded by Terra LaRock, the ...

- **[Mammoth Biosciences plans first trial of triglyceride-lowering gene editing therapy](https://endpoints.news/mammoth-biosciences-plans-first-trial-of-triglyceride-lowering-gene-editing-therapy/)**  
  _Thu, 09 Oct 2025 13:30:56 +0000_  
  SEVILLE, SPAIN — Mammoth Biosciences, a biotech co-founded by Nobel laureate and CRISPR co-inventor Jennifer Doudna, has revealed the first monkey data from its lead program, a gene editing therapy that may permanently lower triglycerides.  ...

- **[Xspray gets CRL over third-party production issues; Oxford Biomedica buys site from Resilience subsidiary](https://endpoints.news/xspray-gets-crl-over-third-party-production-issues-oxford-biomedica-buys-site-from-resilience-subsidiary/)**  
  _Thu, 09 Oct 2025 13:01:01 +0000_  
  Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.

 Xspray Pharma received a complete response letter for its leukemia treatment Dasynoc ...

- **[Finnish researchers report success in mid-stage study of heart disease gene therapy](https://endpoints.news/finnish-researchers-report-success-in-mid-stage-study-of-heart-disease-gene-therapy/)**  
  _Thu, 09 Oct 2025 10:33:04 +0000_  
  SEVILLE, SPAIN — Researchers from the University of Eastern Finland said a gene therapy for people with refractory angina, a form of chronic chest pain that persists despite treatment, was successful in a Phase 2b study ...

- **[Novo Nordisk to buy MASH player Akero for $4.7B upfront](https://endpoints.news/novo-nordisk-to-buy-mash-player-akero-for-4-7b-upfront/)**  
  _Thu, 09 Oct 2025 10:23:59 +0000_  
  Novo Nordisk is to spend $4.7 billion upfront in cash on Akero Therapeutics, a company with a single clinical-stage asset focused on the liver disease MASH.

 The deal follows Roche’s purchase of another MASH specialist ...

- **[How LB Pharma landed the first big US biotech IPO since February](https://endpoints.news/how-lb-pharma-landed-the-first-big-us-biotech-ipo-since-february/)**  
  _Thu, 09 Oct 2025 08:14:36 +0000_  
  In her first interview since taking LB Pharmaceuticals through a $285 million Nasdaq debut last month, CEO Heather Turner spoke with Endpoints News about how the company was able to follow through ...

- **[ARPA-H awards several biotechs funding to make in vivo therapies](https://endpoints.news/arpa-h-awards-several-biotechs-funding-to-make-in-vivo-therapies/)**  
  _Wed, 08 Oct 2025 19:15:18 +0000_  
  ARPA-H has funded seven teams to make in vivo therapies aimed at teaching immune cells to fight disease directly in the body. That includes developing treatments that leverage gene editing and mRNA, among other modalities ...

- **[CBER chief Prasad hires ARPA-H doctor as one of two new acting deputies](https://endpoints.news/cber-chief-prasad-hires-arpa-h-doctor-as-one-of-two-new-acting-deputies/)**  
  _Wed, 08 Oct 2025 18:40:53 +0000_  
  Vinay Prasad, the FDA's biologics chief, told staffers on Monday about the latest changes to leadership in his center, after he abruptly left and then returned to the agency in August.  ...

- **[Q&A: Scientists behind Baby KJ’s custom CRISPR drug are planning to help more children](https://endpoints.news/qa-scientists-behind-baby-kjs-custom-crispr-drug-are-planning-to-help-more-children/)**  
  _Wed, 08 Oct 2025 18:29:20 +0000_  
  SEVILLE, SPAIN — Earlier this year, the long-held dream of personalized gene editing was made real with the creation of a base editing therapy to correct the unique mutation that caused “Baby KJ’s” rare and otherwise ...

- **[Colorado drug board sets first state pricing limit for Amgen’s Enbrel in 2027](https://endpoints.news/colorado-drug-board-sets-first-state-pricing-limit-for-amgens-enbrel-in-2027/)**  
  _Wed, 08 Oct 2025 17:41:32 +0000_  
  Colorado became the first state to set a payment limit for a prescription drug last week, with its drug affordability board agreeing to a nearly 70% reduction off the list price for Amgen’s blockbuster rheumatoid ...

- **[Eccogene files for Hong Kong IPO to back development of GLP-1 pipeline](https://endpoints.news/eccogene-files-for-hong-kong-ipo-to-back-development-of-glp-1-pipeline/)**  
  _Wed, 08 Oct 2025 14:50:39 +0000_  
  Eccogene, a clinical-stage biotech whose oral GLP-1 drug forms the backbone of AstraZeneca’s obesity pipeline, is planning an initial public offering on the Hong Kong Stock Exchange.

 The biotech made public a 550-page


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/biotech/onos-bms-partnered-ep4-antagonist-improves-survival-phase-2-gastric-cancer-trial" hreflang="en">Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test</a>](https://www.fiercebiotech.com/biotech/onos-bms-partnered-ep4-antagonist-improves-survival-phase-2-gastric-cancer-trial)**  
  _Oct 9, 2025 9:39am_  
  Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer.

- **[<a href="https://www.fiercebiotech.com/biotech/expedition-resupplies-phase-2-copd-voyage-165m-series" hreflang="en">Expedition resupplies for phase 2 COPD voyage with $165M series A</a>](https://www.fiercebiotech.com/biotech/expedition-resupplies-phase-2-copd-voyage-165m-series)**  
  _Oct 9, 2025 9:55am_  
  Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstructive pulmonary disease.

- **[<a href="https://www.fiercebiotech.com/biotech/novo-inks-52b-akero-buyout-bag-late-phase-mash-prospect" hreflang="en">Novo inks Akero buyout worth up to $5.2B to bag late-phase MASH prospect</a>](https://www.fiercebiotech.com/biotech/novo-inks-52b-akero-buyout-bag-late-phase-mash-prospect)**  
  _Oct 9, 2025 7:42am_  
  Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market.

- **[<a href="https://www.fiercebiotech.com/biotech/cdmo-catalent-strengthens-adc-pipeline-10m-pact-lisata-tumor-drug" hreflang="en">CDMO Catalent strengthens ADC pipeline with $10M pact for Lisata tumor drug</a>](https://www.fiercebiotech.com/biotech/cdmo-catalent-strengthens-adc-pipeline-10m-pact-lisata-tumor-drug)**  
  _Oct 9, 2025 5:34am_  
  Catalent has continued its foray into the antibody-drug conjugate space, this time penning a $10 million biobucks pact to evaluate Lisata’s tumor drug.

- **[<a href="https://www.fiercebiotech.com/medtech/turbine-looks-turbo-charge-astrazenecas-adc-discovery" hreflang="en">AI discovery outfit Turbine looks to turbocharge AstraZeneca's ADC efforts</a>](https://www.fiercebiotech.com/medtech/turbine-looks-turbo-charge-astrazenecas-adc-discovery)**  
  _Oct 6, 2025 4:16am_  
  AstraZeneca is once again teaming up with Hungarian AI specialist Turbine as it looks to speed up and gain deeper insights into its antibody-drug conjugate discovery process.

- **[<a href="https://www.fiercebiotech.com/biotech/arpa-h-reveals-biotech-winners-vivo-cell-therapy-funding-sweepstakes" hreflang="en">US government pumps money toward in vivo cell therapy programs</a>](https://www.fiercebiotech.com/biotech/arpa-h-reveals-biotech-winners-vivo-cell-therapy-funding-sweepstakes)**  
  _Oct 8, 2025 3:48pm_  
  After axing a vast array of federal research projects and grants, a recent slew of awards paints a picture of the types of science that the second Trump administration will back: in vivo cell therapies.

- **[<a href="https://www.fiercebiotech.com/medtech/oxford-biodynamics-unveils-new-target-use-episwitch-blood-test" hreflang="en">Oxford BioDynamics unveils new target use for EpiSwitch blood test</a>](https://www.fiercebiotech.com/medtech/oxford-biodynamics-unveils-new-target-use-episwitch-blood-test)**  
  _Oct 8, 2025 10:57am_  
  Oxford BioDynamics, a U.K.-based maker of precision diagnostics, touted progress toward a first-of-its-kind blood test for chronic fatigue syndrome.

- **[<a href="https://www.fiercebiotech.com/medtech/bd-opentrons-labs-multi-year-deal-leverage-their-tech-rd-goals" hreflang="en">BD, Opentrons Labs enter multi-year collaboration to join cell analysis, automation tech</a>](https://www.fiercebiotech.com/medtech/bd-opentrons-labs-multi-year-deal-leverage-their-tech-rd-goals)**  
  _Oct 8, 2025 12:22pm_  
  Under a multi-year deal, medtech company BD and lab automation specialist Opentrons Labworks are joining forces to leverage their respective technologies to speed up and boost R&D.

- **[<a href="https://www.fiercebiotech.com/research/sanofi-inks-pact-canadian-tech-company-bring-ai-rd" hreflang="en">Sanofi inks pact with Canadian tech company to bring AI to preclinical R&amp;D</a>](https://www.fiercebiotech.com/research/sanofi-inks-pact-canadian-tech-company-bring-ai-rd)**  
  _Oct 8, 2025 11:55am_  
  Sanofi has found a new preclinical research partner in Canadian software company BenchSci, which will provide the French drugmaker an AI copilot as part of a three-year partnership, BenchSci announced in an Oct. 8 release.

- **[<a href="https://www.fiercebiotech.com/biotech/transcode-rewrites-future-securing-25m-lifeline-and-phase-3-cancer-vaccine" hreflang="en">TransCode rewrites future, securing $25M lifeline and phase 3 cancer vaccine</a>](https://www.fiercebiotech.com/biotech/transcode-rewrites-future-securing-25m-lifeline-and-phase-3-cancer-vaccine)**  
  _Oct 8, 2025 9:03am_  
  In a pair of deals, TransCode has bagged a phase 3 cancer vaccine and a $25 million injection into its cash-strapped coffers.


## Regeneron Press Releases

- **[Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation](https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-rwlc-approved-us-first-and-only)**  
  _Wed, 08 Oct 2025 14:31:00 -0400_  
  Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p0.0001), the primary endpoint of the trial  Libtayo is the current standard of care in


## arXiv q-bio

- **[Neu-RadBERT for Enhanced Diagnosis of Brain Injuries and Conditions](https://arxiv.org/abs/2510.06232)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06232v1 Announce Type: new 
Abstract: Objective: We sought to develop a classification algorithm to extract diagnoses from free-text radiology reports of brain imaging performed in patients with acute respiratory failure (ARF) undergoing invasive mechanical ventilation. Methods: We developed and fine-tuned…

- **[Soft-Evidence Fused Graph Neural Network for Cancer Driver Gene Identification across Multi-View Biological Graphs](https://arxiv.org/abs/2510.06290)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06290v1 Announce Type: new 
Abstract: Identifying cancer driver genes (CDGs) is essential for understanding cancer mechanisms and developing targeted therapies. Graph neural networks (GNNs) have recently been employed to identify CDGs by capturing patterns in biological interaction networks. However, most G…

- **[Retrieving the structure of probabilistic sequences from EEG data during the goalkeeper game](https://arxiv.org/abs/2510.06344)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06344v1 Announce Type: new 
Abstract: This work draws on the conjecture that fingerprints of stochastic event sequences can be retrieved from electroencephalographic data (EEG) recorded during a behavioral task. To test this, we used the Goalkeeper Game (game.numec.prp.usp.br). Acting as a goalkeeper, the p…

- **[Diffusion-Guided Renormalization of Neural Systems via Tensor Networks](https://arxiv.org/abs/2510.06361)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06361v1 Announce Type: new 
Abstract: Far from equilibrium, neural systems self-organize across multiple scales. Exploiting multiscale self-organization in neuroscience and artificial intelligence requires a computational framework for modeling the effective non-equilibrium dynamics of stochastic neural tra…

- **[UniOTalign: A Global Matching Framework for Protein Alignment via Optimal Transport](https://arxiv.org/abs/2510.06554)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06554v1 Announce Type: new 
Abstract: Protein sequence alignment is a cornerstone of bioinformatics, traditionally approached using dynamic programming (DP) algorithms that find an optimal sequential path. This paper introduces UniOTalign, a novel framework that recasts alignment from a fundamentally differ…

- **[Utilizing Information Theoretic Approach to Study Cochlear Neural Degeneration](https://arxiv.org/abs/2510.06671)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06671v1 Announce Type: new 
Abstract: Hidden hearing loss, or cochlear neural degeneration (CND), disrupts suprathreshold auditory coding without affecting clinical thresholds, making it difficult to diagnose. We present an information-theoretic framework to evaluate speech stimuli that maximally reveal CND…

- **[Gradient of White Matter Functional Variability via fALFF Differential Identifiability](https://arxiv.org/abs/2510.06914)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06914v1 Announce Type: new 
Abstract: Functional variability in both gray matter (GM) and white matter (WM) is closely associated with human brain cognitive and developmental processes, and is commonly assessed using functional connectivity (FC). However, as a correlation-based approach, FC captures the co-…

- **[Quantifying spike train synchrony and directionality: Measures and Applications](https://arxiv.org/abs/2510.07140)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.07140v1 Announce Type: new 
Abstract: By introducing the twin concepts of reliability and precision along with the corresponding measures, Mainen and Sejnowski's seminal 1995 paper "Reliability of spike timing in neocortical neurons" (Mainen and Sejnowski, 1995) paved the way for a new kind of quantitative…

- **[ARGscape: A modular, interactive tool for manipulation of spatiotemporal ancestral recombination graphs](https://arxiv.org/abs/2510.07255)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.07255v1 Announce Type: new 
Abstract: Ancestral recombination graphs (ARGs) encode the complete genealogical history of a population of recombining lineages. ARGs, and their succinct representation, tree sequences, are increasingly central to modern population genetics methods, yet building an intuition for…

- **[Entropy and diffusion characterize mutation accumulation and biological information loss](https://arxiv.org/abs/2510.07265)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.07265v1 Announce Type: new 
Abstract: Aging is a universal consequence of life, yet researchers have identified no universal theme. This manuscript considers aging from the perspective of entropy, wherein things fall apart. We first examine biological information change as a mutational distance, analogous t…

- **[Stacked Regression using Off-the-shelf, Stimulus-tuned and Fine-tuned Neural Networks for Predicting fMRI Brain Responses to Movies (Algonauts 2025 Report)](https://arxiv.org/abs/2510.06235)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06235v1 Announce Type: cross 
Abstract: We present our submission to the Algonauts 2025 Challenge, where the goal is to predict fMRI brain responses to movie stimuli. Our approach integrates multimodal representations from large language models, video encoders, audio models, and vision-language models, comb…

- **[Space, time and altruism in pandemics and the climate emergency](https://arxiv.org/abs/2510.06236)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06236v1 Announce Type: cross 
Abstract: Climate change is a global emergency, as was the COVID-19 pandemic. Why was our collective response to COVID-19 so much stronger than our response to the climate emergency, to date? We hypothesize that the answer has to do with the scale of the systems, and not just s…

- **[Coupled opinion-environmental dynamics in polarized and prejudiced populations](https://arxiv.org/abs/2510.06237)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06237v1 Announce Type: cross 
Abstract: Public opinion on environmental issues remains polarized in many countries, posing a significant barrier to the implementation of effective policies. Behind this polarization, empirical studies have identified social susceptibility, personal prejudice, and personal ex…

- **[Improving Artifact Robustness for CT Deep Learning Models Without Labeled Artifact Images via Domain Adaptation](https://arxiv.org/abs/2510.06584)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.06584v1 Announce Type: cross 
Abstract: Deep learning models which perform well on images from their training distribution can degrade substantially when applied to new distributions. If a CT scanner introduces a new artifact not present in the training labels, the model may misclassify the images. Although…

- **[Evolutionary Profiles for Protein Fitness Prediction](https://arxiv.org/abs/2510.07286)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2510.07286v1 Announce Type: cross 
Abstract: Predicting the fitness impact of mutations is central to protein engineering but constrained by limited assays relative to the size of sequence space. Protein language models (pLMs) trained with masked language modeling (MLM) exhibit strong zero-shot fitness predictio…

- **[Emergent predictability in microbial ecosystems](https://arxiv.org/abs/2403.19372)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2403.19372v3 Announce Type: replace 
Abstract: Microbial ecosystems exhibit a surprising amount of functionally relevant diversity at all levels of taxonomic resolution, presenting a significant challenge for most modeling frameworks. A long-standing hope of theoretical ecology is that some patterns might persis…

- **[Advancing glaucoma research with multiphysics continuum mechanics modelling: Opportunities and open challenges](https://arxiv.org/abs/2411.06539)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2411.06539v2 Announce Type: replace 
Abstract: This review examines the emerging role of mechanistic mathematical models based on continuum mechanics to address current challenges in glaucoma research. At present, the advent of Artificial Intelligence and data-based models have resulted in significant progress i…

- **[The generic temperature response of large biochemical networks](https://arxiv.org/abs/2403.17202)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2403.17202v3 Announce Type: replace-cross 
Abstract: Biological systems are remarkably susceptible to relatively small temperature changes. The most obvious example is fever, when a modest rise in body temperature of only few Kelvin has strong effects on our immune system and how it fights pathogens. Another ver…

- **[SafeProtein: Red-Teaming Framework and Benchmark for Protein Foundation Models](https://arxiv.org/abs/2509.03487)**  
  _Thu, 09 Oct 2025 00:00:00 -0400_  
  arXiv:2509.03487v2 Announce Type: replace-cross 
Abstract: Proteins play crucial roles in almost all biological processes. The advancement of deep learning has greatly accelerated the development of protein foundation models, leading to significant successes in protein understanding and design. However, the lack of sy…
